Regrettably, NSCLC patients harboring EGFR exon 20 insertion mutations exhibit poor response to TKIs, which restricts the application of TKIs in EGFR exon 20 insertions (24). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.